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1a,25-Dihydroxyvitamin D3 exerts its actions by binding to vitamin D receptor (VDR). We are continuing
the study related to the alteration of pocket structure of VDR by 22-alkyl substituent of ligands and the
relationships between the alteration and agonistic/antagonistic activity. Previously we reported that
compounds 2 (22-H), 3 (22S-Et), and 4 (22S-Bu) are VDR agonist, partial agonist and antagonist, respec-
tively. Here, we describe the synthesis and biological evaluation of 22S-hexyl analog 5 (22S-Hex), which
was designed to be a stronger VDR antagonist than 4. Unexpectedly, 5 showed partial agonistic but not
antagonistic activity when bound to VDR, indicating that it is not necessarily true that the bulkier the side
chain is, the stronger the antagonistic activity will be. X-ray crystallographic analysis of the VDR–ligand-
binding domain (VDR–LBD) accommodating compound 5 indicated that the partial agonist activity of 5 is
dependent on the mixed population of the agonistic and antagonistic conformations. Binding of com-
pound 5 may not bring the complex into the only antagonistic conformation due to the large conforma-
tional change of the VDR–LBD. From this study it was found that fine tuning of agonistic/antagonistic
activity for VDR is possible by 22-alkyl chain length of ligands.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
1a,25-Dihydroxyvitamin D3 (1a,25-(OH)2D3), 1, is a hormone
that plays a crucial role in the regulation of calcium homeostasis
(Fig. 1). This hormone 1 is also known to be related to cell differen-
tiation and proliferation and immunomodulation.1 These physio-
logical effects are initiated by the binding of the hormone to the
vitamin D receptor (VDR). VDR is a member of nuclear receptors
which act as ligand-dependent transcriptional factor.2 VDR
changes the conformation from inactive form to active form by
ligand binding and then transcripts the target gene.3
As mentioned in our recent review,4 vitamin D is now attracting
attention because of its involvement in many acute and chronic ill-
nesses related to calcium homeostasis, autoimmunity, cancer, dia-betes, and cardiovascular and infectious diseases.5–7 Accordingly,
VDR ligands are expected as drugs to treat these diseases.8,9 To
develop such selective drugs, it is important to understand the
structural basis of interactions between VDR and its ligand.
Several dozen crystal structures of the ligand binding domain
(LBD) of VDR complexed with a ligand have been reported.10 Most
structures are the common active conformation of VDR–LBD and
form a common pocket structure to accommodate the ligand.11
Against such a background we are continuing the study related
to the alteration of pocket structure by 22-alkyl substituent of
the ligands and the relationships between the alteration and ago-
nistic/antagonistic activity.4,12–16 We previously reported that
compounds 2 (22-H), 3 (22S-Et) and 4 (22S-Bu) are VDR agonist,
partial agonist, and antagonist, respectively (Fig. 1).13 Here, we
report on the synthesis and biological evaluation of 22S-hexyl ana-
log 5, which was designed to be a stronger VDR antagonist than 4.
We also report on the X-ray crystallographic analysis of the VDR–
LBD/5 complex and VDR–LBD/3 complex to understand the struc-
tural basis of their agonistic/antagonistic activities.
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Figure 1. Structures of 1a,25-(OH)2D3 1 and its analogs. Compounds 2 and 3 are agonist and partial agonist, respectively. JB and 4 are antagonist. Compound 5 was designed
as a strong VDR antagonist.
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2.1. Synthesis
22S-Hexyl-24-hydroxy-19,25,26,27-tetranorvitamin D analog 5
was synthesized in a similar manner to that reported previously
(Scheme 1).13 Conjugate addition of Hex2CuLi prepared from HexLi
and CuBr/Me2S to Z-enoate 6 in the presence of TMSCl and HMPA
proceeded diastereofacially to provide the 22S-isomer 7 in 62%OTBSTBSO
H
CO2Et
Hex2CuLi
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Scheme 1. Synthetic schyield and 22R-isomer 8 in 10% yield.17 22S-isomer 7 was reduced
with DIBAL-H to give 24-alcohol 9 in 68% yield. Target compound
5 was obtained by deprotection of 9 with CSA in 85% yield.
2.2. Biological activities
Binding affinity for VDR was evaluated with a competitive
binding assay using [3H]-1a,25-dihydroxyvitamin D3 (Fig. 2a).
The IC50 values of 1 and 5 were 0.06 nM and 0.21 nM, respectively,t
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eme of compound 5.
7276 Y. Anami et al. / Bioorg. Med. Chem. 23 (2015) 7274–7281indicating that 22S-hexyl compound 5 has approximately one-
third the VDR affinity of compound 1. Compared to compounds
2–4, the strength order of binding affinity is 4 (22S-Bu) > 5
(22S-Hex) > 3 (22S-Et) > 2 (22-H).
The effect of compound 5 on transcriptional activity was evalu-
ated using a luciferase reporter gene assay in Cos7 cells (Fig. 2b).
Unexpectedly, compound 5 activated VDR and showed moderate
agonistic activity. An inhibition assay using compound 5 was per-
formed in the presence of 108 M of compound 1. Compound 5
inhibited the activity of compound 1 in a concentration-dependent
manner (Fig. 2c). These results indicate that compound 5 is not an
antagonist but a partial agonist.0
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Figure 2. Binding affinity for VDR and transcriptional activity. (a) VDR binding
affinity of compound 5. The affinity was evaluated by competitive binding assay in
duplicate. The IC50 values of 1 and 5 were determined by their concentration at 50%
displacement of [3H]-1a,25-(OH)2D3. (b and c) Effect of compound 5 on transcrip-
tional activity in Cos7 cells. The transcriptional activity of 5 was evaluated at 1010
to 105 M concentrations using dual luciferase assay in triplicate. (c) The inhibition
effect on the transactivation induced by 1 was evaluated in the presence of 108 M
of 1.2.3. X-ray crystal structure analysis
We previously reported the crystal structures of VDR–LBD com-
plexed with agonist 2 (22-H) and antagonist JB (22S-Bu).4,12,15 JB is
recognized as a surrogate of antagonist 4 (22S-Bu). To clarify the
molecular basis of the actions of 22S-alkyl compounds 3–5 relative
to compound 1 and their prototype compound 2 (22-H), we carried
out X-ray crystallographic analysis of VDR–LBD complexed with
22-Et compound 3 and 22-Hex compound 5. X-ray diffraction
images of complexes with 3 and 5 were obtained at 2.9 Å resolu-
tion and 2.2 Å resolution, respectively. Table 1 shows the data col-
lection statistics and refinement. Both crystal structures had a
space group of C2.
Figure 3a–c shows the crystal structure of VDR–LBD/3 complex.
The main chain structure of the protein is almost consistent with
the canonical conformation (PDB 5AWK). The overall pocket struc-
ture is similar to VDR–LBD accommodating ligand 1 or 2, but a
slightly induced cavity in the direction of the butyl pocket was
observed (Figs. 3a, 4b). The 2FO  FC map of ligand 3 is poor
because of the low resolution (2.9 Å), but ligand 3 could be put into
the map as shown in Figure 3b. The original side chain with the 24-
hydroxyl group was accommodated into the canonical pocket and
the 22S-ethyl group was directed to Leu305 (potential butyl
pocket) (Fig. 3a). Interactions including hydrogen bonds between
ligand 3 and VDR–LBD were similar to those of the VDR–LBD/2
complex (Fig. 3c). One difference is the slight shift of the side chain
of Leu305 caused by repulsion with the 22S-ethyl group
(Figs. 3a, 4e).
Figure 3d–j shows the crystal structure of the VDR–LBD/5 com-
plex. The main chain structure of the protein adopted a canonical
conformation (PDB 5AWJ). In this complex, a large butyl pocket
and obvious side chain rotation of Leu305 were observed
(Figs. 3d, 4e). Interestingly, composite omitmap showed that ligand
5 binds to VDR–LBD with major and minor conformations in a ratio
of approximately 6:4 (Fig. 3g–j) and whose side chains are inverted
relative to one another. In the 60% major conformer, the original
side chain with a 24-hydroxy group occupies the canonical pocket
and the 22S-hexyl group occupies the butyl pocket as JB doesTable 1
Summary of data collection statistics and refinement
Ligand 3 5
X-ray source KEK-PF BL-5A SPring-8 BL38B1
Wavelength (Å) 1.00000 1.00000
Space group C2 C2
Unit cell dimensions
Bond (Å) a = 154.03, b = 41.97,
c = 41.86
a = 153.48, b = 44.45,
c = 42.32
Angle () a = 90.00, b = 95.96,
c = 90.00
a = 90.00, b = 100.53,
c = 90.00
Resolution rangea
(Å)
40.48–2.90 (3.10–2.90) 50.00–2.20 (2.28–2.20)
Total no. of
reflections
9246 50,407
No. of unique
reflections
4525 14,125
% completenessa 75.2 (76.8) 98.1 (85.7)
Rmerge
a,b 0.079 (0.309) 0.032 (0.138)
Refinement
statistics
Resolution rangea
(Å)
40.48–2.90 (3.10–2.90) 27.44–2.20 (2.28–2.20)
R factor
(Rfree/Rwork)a,c
0.2677/0.2094 0.2599/0.2139
a Values in parentheses are for the highest-resolution shell.
b Rmerge = R|(Ihkl  hIhkli)|/(RIhkl), where hIhkli is the mean intensity of all reflec-
tions equivalent to reflection hkl.
c Rwork (Rfree) =R||Fobs|  |Fcalc||/R|Fobs|, where 5% of randomly selected data were
used for Rfree.
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Figure 3. X-ray crystal structures of VDR–LBD complexed with 3 (a–c) and 5 (d–j). (a and d) Connolly channel surface of the ligand-binding pocket (LBP) of VDR–LBD/3 (pink)
and VDR–LBD/5 (gray), which were calculated using software SYBYL-X 1.3. (b) The 2FO  FC map and the ligand 3 of VDR–LBD/3 complex are shown as a gray mesh and pink
stick, respectively. (g–j) The composite omit map of VDR–LBD/5 complex was generated using the VDR–LBD without the ligand as a coordinate file and is shown as a gray
mesh. There are three conformations of 5, the major (blue stick) and the minor (yellow and gray sticks) conformers. (j) Superimposition of major and minor conformers of
ligand 5. (c, e and f) The hydrogen bonds between VDR–LBD and ligand, and the hydrophobic interactions between ligand and helix 12 (V414 and F418).
Y. Anami et al. / Bioorg. Med. Chem. 23 (2015) 7274–7281 7277(Fig. 3d and g). In the 40% minor conformer, the original side chain
occupied the butyl pocket and the 22S-hexyl group occupied the
canonical pocket (Fig. 3d, h and i). The minor 40% conformer was
further divided into a 20% conformer in which the terminal methyl
of the 22S-hexyl group adopts different conformations (Fig. 3h and
i). Superimposition of three conformers is consistent with the com-
posite omit map (Fig. 3j). The large butyl pocket induced by com-
pound 5 has a channel opening between helix 7 and helix 10
(Fig. 3d), which matches our previous observation.16In all conformers, the 1a- and 3b-hydroxy groups of the A-ring
formed pincer type hydrogen bonds with Ser233 and Arg270 and
with Tyr143 and Ser274, respectively (Fig. 3e and f). In the major
conformer, the 24-hydroxy group formed a hydrogen bond only
with His393. Hydrophobic interactions with helix 12 were not
observed (Fig. 3e). In the minor conformers, the 24-hydroxy group
formed no hydrogen bond with any amino acid residues, while the
terminal methyl of the hexyl group showed hydrophobic interac-
tions with Val414 and Phe418 on helix 12 (Fig. 3f).
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Figure 4. Connolly channel surface of the LBP of VDR–LBD/22S-alkyl compounds and structural alteration by rotation of Leu305. (a) The LBP of VDR–LBD/2 (green, PDB 3VRT),
which was depicted after generating Leu400 from the stub of the corresponding amino acid residue by examining the 2FO  FC map. (b) The LBP of VDR–LBD/3 (pink), (c) VDR–
LBD/JB (cyan, PDB 2ZXM), and (d) VDR–LBD/5 (gray). (e) Superimposition of VDR–LBD/ligand complexes. Complexes of VDR–LBD with 2, 3, JB, and 5 are depicted in green,
pink, cyan, and blue, respectively. The main chains (nitrogen of amide, a-carbon, and carbonyl carbon) are each shown as a slim stick, ligands are each shown as a stick, and
the side chains of Leu305 are each shown as a thick stick. Leu305 of the VDR–LBD/5 complex was drastically repositioned due to a steric repulsion with 22S-hexyl group,
causing the main chain to move considerably.
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We have previously reported that compounds 2 (22-H), 3 (22S-
Et) and 4 (22S-Bu) are VDR agonist, partial agonist and antagonist,
respectively.13 Here, we designed and synthesized a 22S-hexyl
analog 5 as a stronger VDR antagonist than 4, hypothesizing that
a hexyl side chain bulkier than butyl would extend or break the
butyl pocket, causing compound 5 to be a strong VDR antagonist.
However, biological activities indicated that compound 5 is not
an antagonist but a partial agonist. Specifically, compound 5
restored the agonist activity. The result suggested that an alkyl
chain of appropriate length is needed for a ligand to act as an
antagonist for VDR.
In crystals of the VDR–LBD/5 complex, ligand 5 is accommo-
dated into VDR–LBD with major and minor conformations
(Fig. 3d–j). The binding mode of the major conformer was similar
to that of antagonist JB in the following points: 22S-alkyl group
occupying the butyl pocket, 24-hydroxyl group forming a hydro-
gen bond only with His393 but not His301, and the ligand not
interacting hydrophobically with helix 12. As reported previously
in our papers,12,16 this conformation is thought to be temporary
and less preferred but could be trapped during crystallization pro-
cess by the effects of crystal packing, so this conformation seems to
reflect antagonist binding structure. Therefore, the major con-
former may be a conformation associated with an antagonistic
activity, while minor conformers may be conformations associated
with an agonistic activity. Recently we reported the crystal struc-
ture of VDR–LBD accommodating the partial agonist in which the
ligand binds to VDR–LBD in two conformations, one of which is
the antagonist/VDR–LBD complex structure and the other the ago-nist/VDR–LBD complex structure.16 In that report, we concluded
that partial agonist activity is dependent on the population of ago-
nistic and antagonistic conformations. Similarly, in the present
study, plural conformations were detected in a single crystal, so
it is possible that the partial agonist activity of 5 depends on the
mixed population of agonistic and antagonistic conformations.
Thus, we could again trap conformational subsets of the ligand
and the nuclear receptor in a single crystal.
Ligand 3 bound to VDR–LBDwith a single conformation in a sin-
gle crystal (Fig. 3a–c). Although an obvious butyl pocket was not
induced, a small expanded cavity caused by repulsion with the
ethyl group was observed. The 2FO  FC map of the ligand was
not clear (Fig. 3b). From these results, in the case of partial agonist
3, an inverted side chain conformer like compound 5 may exist in
solution (living cells) although we cannot detect them in the crys-
tals. Because the overall structure and binding mode of VDR–LBD/3
complex were almost the same as those of the VDR–LBD/agonist 2
complex, the crystal structure observed here (Fig. 3a–c) would be
the structure reflecting the agonist conformation but not the
antagonist. The partial agonism of compound 3 may also be con-
trolled by the population of agonistic and antagonistic conforma-
tions also seen in partial agonist 5.
Figure 4 shows the pocket structures of VDR–LBD accommodat-
ing ligand 2 (22-H), 3 (22S-Et), JB (22S-Bu), and 5 (22S-Hex). In the
previous paper,16 we reported that there are two forms of the butyl
pocket in which the first form is induced by the butyl group of the
ligand and the second form is induced by a side chain bulkier than
the butyl group. The first is formed by a small shift in the side chain
of Leu305 (Fig. 4c and e), while the second is formed by a rotamer
of the b-carbon of Leu305 (3WT5, 3WT6, 2HCD18). In the present
Y. Anami et al. / Bioorg. Med. Chem. 23 (2015) 7274–7281 7279study, the latter butyl pocket was observed in the VDR–LBD/5 com-
plex (Fig. 4d), in which Leu305 exists as side chain rotamer and the
a-helix break occurs at the beginning of helix 7 (Fig. 4e). Interest-
ingly, we noticed in both the present and previous studies that the
ligand-binding pocket having the second type of butyl pocket com-
monly accommodates multiple ligand conformers. Although the
co-crystallization was barely achieved, VDR–LBD accommodating
the hexyl group in the large butyl pocket (major conformer) may
be unstable and consequently behave as an antagonist binding
VDR; while VDR–LBD accommodating the hexyl group in the
canonical pocket (minor conformer) may be stable and conse-
quently behave as an agonist binding VDR. The minor conformer
lacks hydrogen bonding with the side chain of the ligand but does
show hydrophobic interactions with the hexyl groups, suggesting
that the hydrophobic interactions may compensate for the disad-
vantage of no hydrogen bonding.
22S-Hexyl compound 5 was designed and synthesized as a
potent VDR antagonist candidate but instead behaved as a partial
agonist. Taken together, compounds 2 (22-H), 3 (22S-Et), 4 (22S-
Bu) and 5 (22S-Hex) are VDR agonist, partial agonist, antagonist,
and partial agonist, respectively. The present study indicates that
it is not necessarily true that the bulkier the side chain is, the
stronger the antagonistic activity will be. Consequently we found
that fine tuning of agonist/antagonist activity for VDR is possible
using a variety of 22-alkyl chain length of ligands.
Several mechanisms of partial agonistic action on nuclear
receptors have been proposed (Fig. 5). First, partial agonist activity
of selective estrogen receptor modulators (SERMs), raloxifene and
tamoxifen, which exert their activity by binding to estrogen
receptor a (ERa), is considered to be dependent on AF-1 domain
but not helix 12 (AF2).19–21 Helix 12 in crystal structures of the
ERa-LBD/SERM complex localizes at the coactivator binding site,
which is thought to be an antagonist binding structure, but SERMs
show partial agonist activity because AF-1 domain retains
transcriptional activity.
The second proposed mechanism is that partial agonist activity
is exerted by a suboptimal conformation upon ligand binding. Pike
et al. reported that helix 12 in the crystal structure of ERb-LBD
complexed with a partial agonist localizes at a position distinctagonist antagonist
partial agonist
Dependence
on the AF-1
Mixed
population
Suboptimal
conformation
Figure 5. The conformation model of nuclear receptor by ligand binding. When
agonist binds to the receptor, helix 12 (H12) is folded and the receptor recruits
coactivator (CoA). When antagonist binds to the receptor, H12 localizes at the CoA
binding site. There are three models that explain partial agonist activity. The first
model is dependent on AF-1. The second model is based on a suboptimal
conformation in which H12 exists in a different position from either the agonistic
or antagonistic position. The third model is based on an average of the population of
agonistic and antagonistic conformations.from the agonistic position and is instead found in a similar orien-
tation to the antagonistic position.22 They considered that this con-
formation results in suboptimal positioning of helix 12. In
peroxisome proliferator-activated receptor c (PPARc) and retinoid
X receptor a, Oberfield et al., Bruning et al. and Ohsawa and
Kawata et al. reported that partial agonists cannot adequately sta-
bilize helix 12 compared to full agonists.23–26
The third proposed mechanism is that partial agonist activity is
dependent on a population of agonistic and antagonistic conforma-
tions. We found that not only 22R-butyl analog16 but also 22S-
hexyl analog 5 bind to VDR–LBD with both agonistic and antago-
nistic conformations in a single crystal. Therefore, we conclude
that partial agonistic activity of the 22R-butyl analog and the
22S-hexyl analog 5 is dependent on the sum of agonistic and
antagonistic behaviors of the ligands on VDR. Nakabayashi et al.
also reported a similar explanation for VDR partial agonism.27
Bourguet et al. and Albers et al. reported that the equilibrium
between the agonist position of helix 12 and its antagonist position
in the coactivator binding groove may then depend on cellular con-
text, and agonistic and antagonistic conformations depend on the
interaction with cofactors (coactivators and corepressors) that help
to stabilize either agonistic or antagonistic conformations, respec-
tively.28,29 Bruning et al. reported that agonistic and antagonistic
conformations could both be detected in each different crystal
structure by using wild type and mutated ERa-LBD.30 Pochetti
et al. also reported that the different binding mode of a partial ago-
nist could be observed in separate crystals that were produced by a
different procedure.31 Recently we reported crystal structures of
the complex of PPARc-LBD and a partial agonist, in which two con-
formations, an active conformation and an alternative conforma-
tion, were observed.32 All these results are consistent with the
proposed mechanism that partial agonist activity is dependent
on the equilibrium between agonistic and antagonistic conforma-
tions. That equilibrium may depend on the cellular context (e.g.,
the concentration of coactivators and corepressors), thus partial
agonists may be potential candidates for pharmaceutical agents
to treat various diseases.4. Conclusion
We designed and synthesized 22S-hexyl analog 5 as a strong
VDR antagonist but found that compound 5 acts as a partial ago-
nist. The crystal structure of the VDR–LBD/5 complex showed that
ligand 5 binds to VDR with two conformations. Binding modes
indicate that the major conformer is the structure associated with
antagonistic activity, while minor conformers are structures asso-
ciated with agonistic activity. Therefore the partial agonist activity
observed with compound 5 may be explained by the mixed popu-
lation of these agonistic and antagonistic conformations. In a series
of 22S-alkyl compounds 2–5, antagonist activity increases in the
order of 2 (H) < 3 (Et) < 4 (Bu), but unexpectedly 5 (Hex) restores
agonist activity. These results indicate that fine tuning of agonis-
tic/antagonistic activity for VDR is possible by 22-alkyl chain
length of ligands. This knowledge will be useful for the design of
novel agonists/antagonists of VDR.5. Experimental
5.1. General procedure
All reagents were purchased from commercial sources. NMR
spectra were recorded with Bruker AV-300 M at 300 MHz for 1H
NMR and 75 MHz for 13C NMR in CDCl3 solution with TMS as an
internal standard and the chemical shifts are given in d values.
High and low resolution mass spectra were obtained with a JEOL
7280 Y. Anami et al. / Bioorg. Med. Chem. 23 (2015) 7274–7281JMS-HX110A and Shimadzu GCMS-QP5050A spectrometers. Rela-
tive intensities are given in parentheses in low mass. IR spectra
were recorded on a Shimadzu FTIR-8400S spectrophotometer,
and data are given in cm1. UV spectra were recorded on a Beck-
man DU7500 spectrophotometer. All air and moisture sensitive
reactions were carried out under argon or nitrogen atmosphere.
Purity was determined by HPLC [Pegasil silica SP100,
4.6 mm  150 mm, hexane/CHCl3/MeOH (100:25:8), flow rate
1.0 mL/min] and was >98.5% for tested compound.
5.2. Synthesis
5.2.1. Ethyl (3S)-3-{1-[(1R,3R,7E,17b)-1,3-bis{[tert-Butyl(dimethyl)
silyl]oxy}-2-methylidene-9,10-secoestra-5,7-dien-17-yl]ethyl}
nonanoate (7)
A suspension of CuBr/Me2S (322 mg, 1.57 mmol) in THF (3 mL)
was cooled to 25 C, and to this solution was added hexyl lithium
(1.35 mL, 3.12 mmol, 2.3 M in hexane) and the mixture was stirred
for 20 min. To this solution was added TMSCl (249 lL, 1.95 mmol),
HMPA (341 lL, 1.95 mmol), and a solution of Z-enoate 6 (83.4 mg,
0.13 mmol) in THF (2 mL) in this order. The mixture was stirred at
25 C for 1.5 h, and the reaction was quenched with 3.6% HCl. The
mixture was extracted with AcOEt. The organic layer was washed
with water and brine, dried over MgSO4 and evaporated. The resi-
due was chromatographed on silica gel (10 g) with 0.5% AcOEt/
hexane to afford 7 (58.4 mg, 62%) and its 22R-isomer 8 (12.6 mg,
10%).
7 1H NMR (300 MHz, CDCl3) d 0.02, 0.05, 0.07, 0.08 (each 3H, s,
SiMe), 0.52 (3H, s, H-18), 0.81 (3H, d, J = 6.2 Hz, H-21), 0.86, 0.90
(each 9H, s, t-Bu), 1.25 (3H, t, J = 7.1 Hz, ACOOEt), 2.82 (1H, m,
H-9), 4.13 (2H, m, ACOOEt), 4.43 (2H, m, H-1, 3), 4.92, 4.97 (each
1H, s, AC@CH2), 5.84 (1H, d, J = 11.1 Hz, H-7), 6.21 (1H, d,
J = 11.1 Hz, H-6). 13C NMR (75 MHz, CDCl3) d 5.1, 4.91, 4.86
(2 carbons), 12.0, 13.2, 14.1, 14.4, 18.2, 18.3, 22.1, 22.7, 23.5,
25.78 (3 carbons), 25.85 (3 carbons), 27.3, 28.0, 28.1, 28.8, 29.7,
31.9, 37.4, 37.8, 38.5, 38.6, 40.7, 45.7, 47.6, 53.8, 56.3, 60.0, 71.6,
72.6, 106.3, 116.2, 122.4, 132.8, 141.1, 153.0, 173.9. MS (EI) m/z
(%) 728 (M+, 2), 596 (34), 539 (9), 366 (31), 234 (14), 147 (14),
73 (100). HRMS (EI) calcd for C44H80O4Si2 (M+) 728.5595, found
728.5603. IR (neat) 3394, 2955, 2928, 2895, 2856, 1738, 1651
1620, 1464, 1256, 1101, 1070, 935, 897, 835, 775 cm1. UV (hex-
ane) kmax 246, 254, 264 nm.
8 (22R-isomer of 7) 1H NMR (300 MHz, CDCl3) d 0.03, 0.05, 0.07,
0.08 (each 3H, s, SiMe), 0.56 (3H, s, H-18), 0.79 (3H, d, J = 6.7 Hz, H-
21), 0.87, 0.89 (each 9H, s, t-Bu), 2.82 (1H, m, H-9), 4.14 (2H, q,
J = 7.2 Hz, ACOOEt), 4.42 (2H, m, H-1, 3), 4.92, 4.97 (each 1H, s,
AC@CH2), 5.84 (1H, d, J = 11.0 Hz, H-7), 6.21 (1H, d, J = 11.2 Hz,
H-6).
5.2.2. (3S)-3-{1-[(1R,3R,7E,17b)-1,3-bis{[tert-Butyl(dimethyl)
silyl]oxy}-2-methylidene-9,10-secoestra-5,7-dien-17-yl]ethyl}
nonan-1-ol (9)
Ester 7 (32.5 mg, 0.0446 mmol) in CH2Cl2 (1 mL) was treated
with DIBAL-H (140 lL of 1.0 M toluene solution, 0.14 mmol) at
0 C for 0.5 h. The reaction was quenched with Rochelle salt aq
solution and extracted with CH2Cl2. The organic layer was washed
with brine, dried over MgSO4 and evaporated. The residue was
chromatographed on silica gel (5 g) with 5% AcOEt/hexane to
afford 9 (22.6 mg, 68%).
9 1H NMR (300 MHz, CDCl3) d 0.03, 0.05, 0.06, 0.08 (each 3H, s,
SiMe), 0.54 (3H, s, H-18), 0.81 (3H, d, J = 6.2 Hz, H-21), 0.86, 0.90
(each 9H, s, t-Bu), 2.82 (1H, m, H-9), 3.65 (2H, m, H-24), 4.43
(2H, m, H-1, 3), 4.92, 4.97 (each 1H, s, AC@CH2), 5.83 (1H, d,
J = 11.2 Hz, H-7), 6.22 (1H, d, J = 11.1 Hz, H-6). 13C NMR(75 MHz,
CDCl3) d 5.1, 4.91, 4.86 (2 carbons), 12.0, 13.3, 14.1, 18.2,
18.3, 22.2, 22.7, 23.5, 25.78 (3 carbons), 25.85 (3 carbons), 27.8,28.5, 28.7, 28.8, 29.9, 32.0, 35.3, 36.5, 38.0, 38.6, 40.7, 45.7, 47.6,
53.8, 56.3, 61.9, 71.6, 72.6, 106.3, 116.2, 122.4, 132.8, 141.1, 153.0.
5.2.3. 22S-Hexyl-2-methylidene-19,25,26,27-tetranor-1a,25-
dihydroxyvitamin D3 (5)
A solution of 9 (22.6 mg, 0.0305 mmol) and camphor sulfonic
acid (22.3 mg, 0.096 mmol) in MeOH (1 mL) was stirred at room
temperature for 2 h. Aqueous NaHCO3 was added and the mixture
was extracted with AcOEt. The organic layer was washed with
brine, dried over MgSO4 and evaporated. The residue was chro-
matographed on silica gel (5 g) with 70% AcOEt/hexane to afford
5 (11.9 mg, 85%).
5 1H NMR (300 MHz, CDCl3) d 0.55 (3H, s, H-18), 0.80 (3H, d,
J = 6.4 Hz, H-21), 0.88 (3H, m, H-methyl of hexyl), 3.64 (2H, m, H-
24), 4.47 (2H, m, H-1, 3), 5.09, 5.11 (each 1H, s, AC@CH2), 5.88
(1H, d, J = 11.3 Hz, H-7), 6.35 (1H, d, J = 11.2 Hz, H-6). 13C NMR
(75 MHz, CDCl3) d 12.0, 13.3, 14.1, 22.2, 22.7, 23.5, 27.8, 28.5,
28.7, 29.0, 29.9, 32.0, 35.3, 36.5, 38.0, 38.2, 40.5, 45.8 (2 carbons),
53.8, 56.4, 61.9, 70.7, 71.8, 107.7, 115.3, 124.2, 130.5, 143.3,
152.0. MS (EI) m/z (%) 458 (M+, 40), 315 (21), 297 (25), 287 (13),
269 (18), 251 (19), 169 (47), 161 (44), 135 (100). HRMS (EI) calcd
for C30H50O3 (M+) 458.3760, found 458.3770. IR (neat) 3356,
2926, 2856, 1715, 1659, 1620, 1452, 1377, 1045, 756 cm1. UV
(EtOH) kmax 246, 254, 263 nm. Purity was determined by HPLC
[Pegasil silica SP100, 4.6 mm  150 mm, hexane/CHCl3/MeOH
(100:25:8), flow rate 1.0 mL/min] and was >98.5%.
5.3. Binding affinity
The binding affinity for VDR–LBD was evaluated according to
the procedure reported previously.13,33
5.4. Transactivation
Transactivation in Cos7 cells was measured by dual luciferase
assay according to the procedure reported previously.13,33
5.5. Crystallographic analysis
5.5.1. Protein expression and purification
Expression of rat VDR–LBD (residues 116–423, D165–211) and
the following cell-lysis and centrifugation were done by the proce-
dure reported previously.15,16
5.5.2. Crystallization of VDR–LBD/3
A mixture of rat VDR–LBD in buffer (10 mM Tris–HCl, pH 7.0,
2 mM NaN3, 2 mM TCEP) and a ligand (5 equiv) was incubated at
room temperature for 30 min. Then coactivator peptide (H2-
NAKNHPMLMNLLKDNACONH2) derived from DRIP205 including
receptor interacting domain 2 in buffer (25 mM Tris–HCl, pH 8.0,
50 mM NaCl, 2 mM TCEP, 2 mM NaN3) was added. The mixture
of VDR–LBD/ligand/peptide was allowed to crystallize by the vapor
diffusion method using a series of precipitant solutions containing
0.1 MMOPS-Na (pH 7.0), 0.075–0.2 M sodium formate, 12–22% (w/
v) PEG4000, and 5% ethylene glycol. Droplets for crystallization
were prepared by mixing 1 lL of complex solution and 1 lL of pre-
cipitant solution, and droplets were equilibrated against 300 lL of
precipitant solution at 20 C. The mixture was stored at 20 C, and
crystals appeared after a few days.
5.5.3. Crystallization of VDR–LBD/5
Purified rat VDR–LBD solution in buffer (10 mM Tris–HCl, pH
7.0, 0.02 % (w/v) NaN3, 10 mM DTT) was concentrated to about
0.75 mg/mL by ultrafiltration. To an aliquot (400 lL) of the protein
solution was added a ligand (10 equiv) and the solution was incu-
bated overnight at 4 C. The solution was further concentrated to
Y. Anami et al. / Bioorg. Med. Chem. 23 (2015) 7274–7281 7281attain about 65 lL, and then coactivator peptide (H2NA
KNHPMLMNLLKDNACONH2) derived from DRIP205 including
receptor interacting domain 2 in buffer (25 mM Tris–HCl, pH 8.0,
50 mM NaCl, 10 mM DTT, 0.02 % (w/v) NaN3) was added. The mix-
ture of VDR–LBD/ligand/peptide was allowed to crystallize by the
vapor diffusion method using a series of precipitant solutions con-
taining 0.1 M MOPS-Na (pH 7.0), 0.05–0.2 M sodium formate, 12–
22% (w/v) PEG4000, and 5% ethylene glycol. Droplets for crystal-
lization were prepared by mixing 2.8 lL of complex solution and
1.4 lL of precipitant solution, and droplets were equilibrated
against 500 lL of precipitant solution at 20 C. The mixture was
stored at 20 C, and crystals appeared after a few days.5.5.4. X-ray crystallographic analysis
Prior to diffraction data collection, crystals were soaked in a
cryoprotectant solution containing 0.1 M MOPS-Na (pH 7.0),
0.075–0.2 M sodium formate, 12–22% (w/v) PEG4000, and 18–
22% ethylene glycol. Diffraction data sets of VDR–LBD/3 complex
and VDR–LBD/5 complex were collected at 100 K in a stream of
nitrogen gas at beamline BL-5A of KEK-PF (Tsukuba, Japan) and
BL38B1 of Spring-8 (Sayou, Japan), respectively. Reflections were
recorded with an oscillation range per image of 1.0. Diffraction
data were indexed, integrated, and scaled using the program
iMOSFLM34,35 or HKL2000.36 The structures of ternary complex
were solved by the procedure reported previously.16 The compos-
ite omit map of the VDR–LBD/5 complex (calculated in CNS
ver.1.337,38) was generated using VDR–LBD without the ligand as
a coordinate file. The coordinate data for the structures were
deposited in Protein Data Bank with accession numbers 5AWK
(VDR–LBD/3 complex), and 5AWJ (VDR–LBD/5 complex).Author contribution
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